Index of drugs

Treatment of chronic cerebral insufficiency, including conditions after ischemic stroke and vascular dementia. Mitigation of mental and neurological symptoms of cerebral circulation failure. Treatment of chronic circulatory disorders in choroid and retina. Treatment of vascular disorders.

1 tabl contains 5 mg or 10 mg of vinpocetine. The preparation contains lactose.

Vinpocetine is a compound with a complex mechanism of action, positively influencing brain metabolism and blood flow in the brain, as well as the rheological properties of blood. It has a protective effect on the nervous tissue: it alleviates the detrimental effect of cytotoxic reactions caused by amino acids, intensifies the neuroprotective effect of adenosine and, depending on the concentration, blocks sodium and Calcium channels and inhibits the action of NMDA and AMPA receptors. Vinpocetine stimulates brain metabolism: increases brain Glucose and oxygen consumption, increases brain cell tolerance to hypoxia, increases glucose transport across the blood-brain barrier, changes glucose metabolism to a more favorable energy pathway, selectively inhibits the cGMP-PDE phosphodiesterase-dependent isozyme Ca complex²⁺-calmodulin, as a result of which the concentration of cAMP and cGMP increases in the brain and relaxes the smooth muscle of the blood vessels. Vinpocetine increases ATP levels and ATP / AMP ratio in the brain, increases the metabolism of noradrenaline and serotonin in the brain, stimulates the noradrenergic system and has antioxidant effects. Vinpocetine improves brain microcirculation: it inhibits platelet aggregation, reduces pathologically increased blood viscosity, increases the ability to deform erythrocytes and inhibits the uptake of adenosine by erythrocytes, facilitates oxygen transport to the brain tissue by reducing the affinity of oxygen to erythrocytes. Selectively increases blood flow through cerebral vessels: increases the cerebral fraction of cardiac output, reduces the resistance of cerebral vessels without altering the systemic circulation parameters. Vinpocetine does not cause stealing effect - it improves the perfusion of areas with impaired blood supply, without causing changes in places with proper blood flow. After oral administration, the drug is rapidly absorbed from the gastrointestinal tract. C_max in plasma occurs after 1 hour after administration. Plasma protein binding is 66%. Total bioavailability is 7%. The clearance of vinpocetine is greater than the hepatic clearance, which indicates the extrahepatic metabolism of the drug. T_0,5 It is about 5 hours. The drug is excreted in the urine (60%) and faeces (40%).

Hypersensitivity to the components of the preparation. acute haemorrhagic stroke. Severe ischemic heart disease. Severe heart rhythm disturbances. Pregnancy and breastfeeding. Children (due to lack of sufficient data).

It is recommended to perform ECG monitoring in patients with long QT syndrome or those taking concomitant medications that prolong the QT interval. Due to the lactose content, tablets should not be used in patients with rare galactose intolerance, Lapp lactase deficiency or malabsorption of glucose-galactose.

The drug is contraindicated during pregnancy and breastfeeding.

Uncommon: sleep disorders (insomnia, drowsiness), headache and dizziness, weakness, changes in blood pressure (mainly lowering), headache, nausea, heartburn, dry mouth, increased liver enzymes, allergic skin reactions, depression ST segment, ST segment elongation, tachycardia, additional contractions. Rare: abdominal pain, leukopenia.

Orally. Adults.Table. 5 mg: 1-2 tabl. Three times a day; maintenance dose: 1 tablet 3 times a day.Table. forte 10 mg: 1 tabl. 3 times a day. There is no need to change the dose in patients with liver or kidney disease. The tablets should be taken after a meal.